OverviewSuggest Edit

Orthofix is a medical device company focused on musculoskeletal products and therapies. It operates Orthofix Spine and Orthofix Extremities business units. The company develops, manufactures, and distributes reconstruction and regenerative spine and extremity products that empower surgeons to meet the needs of their patients.
TypePublic
Founded1980
HQLewisville, TX, US
Websiteorthofix.com
Employee Ratings3.4
Overall CultureC

Latest Updates

Employees (est.) (Dec 2019)1,055(+11%)
Job Openings67
Revenue (FY, 2020)$406.6 M(-11%)
Share Price (Apr 2022)$32.3(-7%)
Cybersecurity ratingBMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Orthofix

Jon Serbousek

Jon Serbousek

Director, President, and Chief Executive Officer
Jill Mason

Jill Mason

Chief Ethics and Compliance Officer
Kimberley Elting

Kimberley Elting

Chief Legal and Development Officer
Doug Rice

Doug Rice

Chief Financial Officer
Ehab Esmail

Ehab Esmail

Senior Vice President of Quality, Regulatory and Clinical Affairs
Roberto Donadello

Roberto Donadello

Senior Vice President, Global Operations
Show more

Orthofix Office Locations

Orthofix has offices in Lewisville, Sunnyvale, Sao Paulo, Arcueil and in 5 other locations
Lewisville, TX, US (HQ)
3451 Plano Pkwy
Sunnyvale, CA, US
501 Mercury Dr
Sao Paulo, BR
Alameda Santos, 1978 - conj 162, 16°andar - Jardim Paulista
Arcueil, FR
28 Villa Baudran 24
Paris, FR
259 Rue Saint-Honoré
Ottobrunn, DE
5 Siemensstraße
Show all (9)

Orthofix Financials and Metrics

Orthofix Revenue

Embed Graph
View revenue for all periods
Orthofix's revenue was reported to be $406.56 m in FY, 2020
USD

Revenue (Q1, 2021)

105.6m

Gross profit (Q1, 2021)

79.7m

Gross profit margin (Q1, 2021), %

75.5%

Net income (Q1, 2021)

(5.8m)

EBIT (Q1, 2021)

(2.9m)

Market capitalization (22-Apr-2022)

637.8m

Closing stock price (22-Apr-2022)

32.3

Cash (31-Mar-2021)

94.6m

EV

563.5m
Orthofix's current market capitalization is $637.8 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

433.8m453.0m460.0m406.6m

Revenue growth, %

4%2%

Cost of goods sold

93.0m96.6m100.6m101.9m

Gross profit

340.8m356.4m359.3m304.7m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

108.7m111.5m111.7m109.1m115.9m113.5m104.8m73.1m111.0m105.6m

Cost of goods sold

24.1m22.8m24.0m23.7m25.8m24.9m23.4m23.2m26.2m25.9m

Gross profit

84.6m88.7m87.7m85.4m90.0m88.6m81.4m50.0m84.7m79.7m

Gross profit Margin, %

78%80%78%78%78%78%78%68%76%75%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

81.2m69.6m69.7m96.3m

Accounts Receivable

63.4m77.7m86.8m72.4m

Prepaid Expenses

25.9m17.9m20.9m16.5m

Inventories

81.3m76.8m82.4m84.6m
Quarterly
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

6.2m13.8m(28.5m)2.5m

Depreciation and Amortization

20.1m18.7m24.7m30.5m

Inventories

(15.6m)9.7m(5.7m)(873.0k)

Accounts Payable

2.3m(170.0k)2.1m2.5m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

5.2m6.2m4.9m897.0k350.0k(40.1m)25.7m7.2m11.9m(5.8m)

Depreciation and Amortization

4.4m8.9m13.7m5.7m11.9m18.2m6.3m13.3m22.3m7.4m

Inventories

1.7m5.3m6.9m(2.5m)(2.4m)(5.0m)(848.0k)468.0k246.0k16.0k

Accounts Payable

(4.5m)(3.8m)(2.8m)1.9m1.6m447.0k28.0k(4.8m)(3.1m)(1.5m)
USDFY, 2017

Revenue/Employee

505.6k

Financial Leverage

1.4 x
Show all financial metrics

Orthofix Revenue Breakdown

Embed Graph

Orthofix revenue breakdown by business segment: 42.9% from Bone Growth Therapies, 22.3% from Orthofix Extremities, 20.6% from Spinal Implants and 14.2% from Biologics

Orthofix revenue breakdown by geographic segment: 78.7% from United States and 21.3% from Other

Orthofix Cybersecurity Score

Cybersecurity ratingPremium dataset

B

80/100

SecurityScorecard logo

Orthofix Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Orthofix Online and Social Media Presence

Embed Graph

Orthofix Company Culture

  • Overall Culture

    C

    67/100

  • CEO Rating

    D-

    55/100

  • Compensation

    B+

    78/100

  • Diversity

    B

    72/100

Learn more on Comparably

Orthofix News and Updates

Global $10.3 Billion Sports Medicine Technologies and Markets to 2026 Featuring Anika Therapeutics, Bioventus, DePuy Synthes, Emcyte, Medtronic, Orthofix, Smith & Nephew, and Stryker

Dublin, Nov. 08, 2021 (GLOBE NEWSWIRE) -- The "Sports Medicine: Technologies and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Medical device maker Orthofix warns that Q3 revenue will rise only in low-single digits as COVID delays procedures

Orthofix Medical Inc. said Wednesday it expects third-quarter revenue growth to come in at a low single-digit increase over the year-earlier period, hurt by the high volume of elective procedures that have been deferred or rescheduled in the U.S. and overseas because of the recent surge in cases of…

Orthofix Announces Board Chair Transition

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced that Ron Matricaria, Chairman of the Orthofix Board of Directors since 2014, has decided not to stand for re-election at the Company’s 2021 Annual Meeting in order to focus on ot…

Orthofix Launches Nationwide Recycling Program to Improve Sustainability

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced the launch of a nationwide recycling program to improve sustainability efforts. Orthofix is the first and only company in the U.S. to offer a free recycling program so patients c…

Orthofix Announces US and European Full Market Launch of FITBONE Limb-Lengthening System

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced the U.S. and European full market launch of the FITBONE® intramedullary lengthening system for limb lengthening and deformity correction of the femur and tibia bones

Orthofix Schedules Fourth Quarter and Full Year Earnings Release and Conference Call for February 26, 2021

Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and extremities focus, today announced that it plans to release financial results for the fourth quarter and full year 2020 before market open on Friday, February 26, 2021. Jon Serbousek, President and Chief Executive …
Show more

Orthofix Blogs

FDA Approves AccelStim Bone Healing Therapy Device and Expands Orthofix’s Portfolio of Bone Growth Stimulation Solutions

LEWISVILLE, Texas–(BUSINESS WIRE)– Orthofix Medical Inc. (NASDAQ:OFIX), a global medical device company with a spine and orthopedics focus, today announced the U.S. Food and Drug Administration (FDA) pre-market approval for the AccelStim™ bone healing therapy Class III device. The AccelStim device p…

Orthofix Teams Up with Olympian and Spine Patient Laura Wilkinson

Your browser does not support the video tag. Orthofix is a Proud Sponsor of Olympian Laura Wilkinson “In order to do things no one has ever done, you have to be willing to do things no one else is willing to do.” Laura Wilkinson made history at the 2000 Olympics when she became the first… The post O…

Orthofix Supports Medical and Relief Efforts in Ukraine

Orthofix is supporting the humanitarian efforts underway in Ukraine and neighboring countries through a $25,000 donation to the International Medical Corps. Inside Ukraine and the surrounding region, the International Medical Corps’ teams are responding to this crisis by expanding access to medical …

Olympian and Orthofix Patient Laura Wilkinson Goes for the Gold Once Again

Your browser does not support the video tag. Orthofix is a proud sponsor of Olympian Laura Wilkinson for the Olympic Games, now scheduled for summer 2021 “In order to do things no one has ever done, you have to be willing to do things no one else is willing to do.” Laura Wilkinson made history…

Orthofix Launches O-GENESIS Graft Delivery System and New Hydrated, Ready-to-Use AlloQuent Structural Allograft Q-PACK

Orthofix Launches O-GENESIS Graft Delivery System and New Hydrated, Ready-to-Use AlloQuent Structural Allograft Q-PACK Content Import Wed, 10/07/2020 - 07:00 Orthofix Launches O-GENESIS Graft Delivery System and New Hydrated, Ready-to-Use AlloQuent Structural Allograft Q-PACK …

Orthofix Announces Presentation of Clinical and Scientific Abstracts During the North American Spine Society Annual Meeting

Orthofix Announces Presentation of Clinical and Scientific Abstracts During the North American Spine Society Annual Meeting Content Import Tue, 10/06/2020 - 07:01 Orthofix Announces Presentation of Clinical and Scientific Abstracts During the North American Spine Society Annual Meeting …
Show more

Orthofix Frequently Asked Questions

  • When was Orthofix founded?

    Orthofix was founded in 1980.

  • Who are Orthofix key executives?

    Orthofix's key executives are Jon Serbousek, Jill Mason and Kimberley Elting.

  • How many employees does Orthofix have?

    Orthofix has 1,055 employees.

  • What is Orthofix revenue?

    Latest Orthofix annual revenue is $406.6 m.

  • What is Orthofix revenue per employee?

    Latest Orthofix revenue per employee is $385.4 k.

  • Who are Orthofix competitors?

    Competitors of Orthofix include Medtronic, Bioventus and Mammotome.

  • Where is Orthofix headquarters?

    Orthofix headquarters is located at 3451 Plano Pkwy, Lewisville.

  • Where are Orthofix offices?

    Orthofix has offices in Lewisville, Sunnyvale, Sao Paulo, Arcueil and in 5 other locations.

  • How many offices does Orthofix have?

    Orthofix has 9 offices.